ESR2 and myeloid sarcoma: Thus, preclinical findings here using cell-specific deletion of ERβ in female mice (Fig. 5), transcriptomics of astrocytes when ERβ is selectively deleted (Fig. 6), and ERβ ligand treatment in female mice (Fig. 8) warrant discussion with respect to a Phase 2 trial using treatment with estriol in women with MS, ages 18–50 years93.